Neion Bio is building a biomanufacturing platform that re-engineers living cells into scalable, self-replicating bioreactors for producing biologics like monoclonal antibodies, enzymes, and peptides. The company's Raptor platform combines next-generation genetic engineering and stem cell biology to lower costs, improve batch consistency, and enable rapid scale-up for biopharma partners. It manufactures molecules for both therapeutic and non-therapeutic use at any scale, with site flexibility and fast ramp-up.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional biomanufacturing is expensive, slow to scale, highly variable from batch to batch, and vulnerable to supply chain shocks. These limitations make life-saving biologic medicines costly and difficult to produce reliably at the volumes needed for widespread patient access.
Solution
Neion Bio harnesses nature's most efficient protein factories—living cells—and re-engineers them into autonomous, self-replicating bioreactors capable of converting simple inputs like grain and water into complex biological products. The Raptor platform combines next-generation genetic engineering with stem cell biology to manufacture any biomolecule at scale, including monoclonal antibodies, multi-specifics, enzymes, cytokines, fusion proteins, and peptides. This approach delivers lower-cost, higher-consistency biological molecules while offering site flexibility and rapid ramp-up capabilities. The platform is designed to make medicine production as affordable and accessible as food production, addressing both therapeutic and non-therapeutic applications.
Target Audience
Primary customers are biopharma companies seeking lower-cost, higher-consistency biologic manufacturing, including developers of monoclonal antibodies, enzymes, and other protein-based therapeutics or reagents.
Features
- Raptor platform uses living cells as self-replicating 3D printers, converting simple inputs into complex protein outputs
- Combines next-generation genetic engineering with stem cell biology for scalable biomanufacturing
- Manufactures a broad range of biologics: monoclonal antibodies, multi-specifics, enzymes, cytokines, fusion proteins, peptides, and therapeutic proteins
- Supports both therapeutic and non-therapeutic use cases at any production scale
- Offers site flexibility and rapid ramp-up to respond to supply chain demands
- Focuses on reducing batch-to-batch variability and lowering production costs compared to traditional methods